For clinical epidemiologic and proteomic studies, the control of preanalytic variation, including sample processing and storage, is important. We evaluated the stability of progastrin-releasing peptide (ProGRP) as a marker for the quality control of stored serum and plasma samples. The ProGRP from 23 healthy volunteers was measured serially for 8 hours at room temperature, and the results were validated with clinical samples from the biobank. A significant difference in ΔProGRP was also noted between good-quality (time delay <4 hours before storage) and poor-quality (time delay ≥4 hours before storage) specimens (mean ± SD, 0.17 ± 0.08 vs 0.36 ± 0.14; P < .001; Wilcoxon signed-rank test). With a ΔProGRP cutoff of 0.22, the sensitivity and specificity of detection of the poor-quality samples were 85.7% and 75.0%, respectively, in clinical validations. We demonstrated that ΔProGRP could be used as a marker for quality control in sample processing and storage in biobanks.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1309/AJCPDY5FPQOWA2NA | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Evaluation of Urinary HE4, CEA, ProGRP, CYFRA 21-1 and NSE in the Diagnosis of Lung Cancer.
Ann Clin Lab Sci
November 2024
Department of Clinical Laboratory Medicine, the First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Laboratory Medicine, Jinan, China
Objective: Urinary proteins are effective tumor biomarkers. Human epididymis protein 4 (HE4), progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), cytokeratin-19 fragment 21-1(CYFRA 21-1), and neuron-specific enolase (NSE) in serum, were proposed as tumor biomarkers of lung cancer. Our aim was to identify the urine protein biomarkers that can distinguish patients with lung cancer from healthy individuals and/or patients with benign lung disease with a high level of sensitivity and specificity.
View Article and Find Full Text PDFFirst-line combination therapy of immunotherapy plus anti-angiogenic drug for thoracic SMARCA4-deficient undifferentiated tumors in AIDS: a case report and review of the literature.
Front Immunol
January 2025
Department of Respiratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) exhibit a notably aggressive phenotype, which is associated with poor patient survival outcomes. These tumors are generally resistant to conventional cytotoxic chemotherapy, thereby limiting the availability of effective treatment options.
Case Presentation: We describe a 69-year-old AIDS patient who initially presented with a fused, enlarged lymph node on the right clavicle and mild, unexplained pain under the right axilla that worsened with severe coughing episodes.
Serum progastrin-releasing peptide in pneumonia, chronic obstructive pulmonary disease and early-stage primary lung cancers.
Biochem Med (Zagreb)
February 2025
Clinical Institute of Laboratory Diagnostics, University Hospital Centre Osijek, Osijek, Croatia.
Introduction: Higher concentrations of the small-cell lung cancer (SCLC) serum marker, pro-gastrin-releasing peptide (proGRP), in lung inflammations has been indicated in literature. The objective of this study was to compare serum proGRP concentration in pneumonia, chronic obstructive pulmonary disease (COPD) and early-stage primary lung cancers.
Materials And Methods: An observational study was performed to assess serum proGRP against other lung cancer markers in pneumonia, COPD and in stage 1/2 carcinomas.
Article Synopsis
- * A case study presented a 77-year-old man diagnosed with mixed neuroendocrine prostate cancer, showing high levels of specific tumor markers and multiple metastases.
- * Remarkably, the patient responded positively to a new triplet therapy combining darolutamide, androgen deprivation, and docetaxel, resulting in reduced tumor size and lower serum markers, marking a potential breakthrough in treatment.
The rare case of synchronous bilateral breast metastasis from a lung neuroendocrine tumor (small cell lung carcinoma): a case report and literature review.
Surg Case Rep
September 2024
Department of Diagnostic Pathology, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama, Kawasaki, Kanagawa, 214-0021, Japan.
Background: Breast metastasis from small cell neuroendocrine carcinoma (SNEC) is very rare. In the present report, we describe a case of a female patient who was initially diagnosed with triple negative primary bilateral breast cancer, but during systemic examination, the diagnosis was bilateral breast metastasis from SNEC.
Case Presentation: A 62-year-old woman with no history of smoking presented to the Department of General Medicine with left-sided chest pain, and computed tomography revealed masses in both breasts and left pleural thickening that was further confirmed by mammography and ultrasound of the breasts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!